[{"countryName":"Worldwide","languageLinks":[{"languageName":"English","languageUrl":"/en.html"}]},{"countryName":"USA","languageLinks":[{"languageName":"English","languageUrl":"/en-us.html"}]},{"countryName":"Japan","languageLinks":[{"languageName":"Japanese","languageUrl":"/jp/ja.html"}]}]
The link you have selected will take you outside of the Roche Sequencing Worldwide website.
Overview
The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy assay that’s specially designed and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer (CRC). The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1
Features and Benefits of AVENIO ctDNA Surveillance Kits
- Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
- Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
- Includes reagents, bioinformatics and software
- Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
Product Highlights
Detection of all four mutation classes with exceptional sensitivity and specificity2,3
- >99% specificity for all classes of mutations
- >99% positive predictive value (PPV) for SNVs, indels, and fusions and >96% PPV for CNVs
View performance data showing >99% sensitivity and PPV for all four classes of mutations using the AVENIO ctDNA Surveillance Kit.
View the detailed gene list for the AVENIO Surveillance Panel
A portfolio of NGS liquid biopsy assays
The AVENIO ctDNA Surveillance Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 77-gene AVENIO ctDNA Expanded Kit for profiling emerging and guideline-driven biomarkers.
- National Comprehensive Cancer Network. October 15, 2016.
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554.
- Data on file.